Faron Pharmaceuticals is at the forefront of developing innovative immunotherapies aimed at combating cancer, particularly through its lead product, bexmarilimab. This first-in-class humanized monoclonal antibody specifically targets the Clever-1 receptor found on myeloid cells and macrophages, which are known to play a significant role in tumor growth and immune evasion. By binding to Clever-1, bexmarilimab reprograms the tumor microenvironment, shifting macrophages from an immunosuppressive (M2) state to an immunostimulatory (M1) state. This transformation enhances the immune system's ability to recognize and attack tumors, thereby improving therapeutic outcomes in both hematological malignancies and solid tumors.

Faron's clinical development efforts are exemplified by the ongoing BEXMAB trial, which investigates the safety and efficacy of bexmarilimab in combination with standard therapies for relapsed/refractory acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS). The trial has shown promising results, indicating that bexmarilimab is well tolerated and exhibits efficacy across various patient cohorts. Faron's commitment to advancing macrophage-targeting therapies, alongside its focus on precision medicine and biomarker-driven patient selection, positions the company as a pioneer in the immuno-oncology landscape, with the potential to address significant unmet medical needs in cancer treatment.

Finland

Faron is a clinical stage biopharmaceutical company developing novel treatments for medical conditions with significant unmet needs. Its lead program is bexmarilimab, its investigative precision immunotherapy in Phase I/II development as a novel macrophage checkpoint immunotherapy for patients with hematological malignancies. Bexmarilimab is a novel anti-Clever-1 antibody with the ability to switch immune suppression to immune activation. Faron is based in Turku, Finland and Boston, Massachusetts. Faron is listed on AIM under the ticker ‘FARN’ and Nasdaq First North Growth Market ("Nasdaq First North") under ticker FARON.

Faron

Company Details